1
|
Ben Waer F, Alexe DI, Lahiani M, Sanchez-Gomez R, Chaari F, Alexe CI, Tohanean DI, Rebai H, Iconomescu TM, Talaghir LG, Sahli S. Pilates versus Zumba training effects on postural control under conflicting sensory conditions in postmenopausal women. Exp Gerontol 2024; 188:112383. [PMID: 38377666 DOI: 10.1016/j.exger.2024.112383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Revised: 02/13/2024] [Accepted: 02/17/2024] [Indexed: 02/22/2024]
Abstract
The current study aimed to compare the effects of Pilates versus Zumba training on postural performance in middle-aged postmenopausal women. Fifty-seven eligible women, aged between 50 and 60 years, were randomized into three groups: Zumba (ZG) group, Pilates (PG) group or control (CG) group. Postural control was assessed using a force platform under 4 sensory manipulation conditions: on firm and foam surfaces with eyes opened (EO) and closed (EC). Our results showed more marked adaptations in favor of ZG concerning postural performance compared to PG. For the PG, postural control was significantly improved only in simple postural conditions on the firm surface with EO (p < 0.1) and EC (p < 0.05) conditions. However, postural control of the ZG significantly improved in both the simple and complex postural conditions, even under conflicting sensory situations (firm surface/EO (p < 0.001; 95 % CI: [1.34, 4.46]), EC (p < 0.001; 95 % CI: [2.13, 5.24])); foam surface/EO (p < 0.01; 95 % CI: [0.70, 8.57]), EC (p < 0.01; 95 % CI: [0.65, 8.52])). In conclusion, Zumba training seems to be more effective and a better strategy to promote postural control in daily living activities and autonomy in postmenopausal women than Pilates training. These findings are useful for public health practitioners in designing physical interventions for balance disorders.
Collapse
Affiliation(s)
- Fatma Ben Waer
- Research Laboratory Education, Motricité, Sport et Santé, LR19JS01, High Institute of Sport and Physical Education of Sfax, University of Sfax, Tunisia
| | - Dan Iulian Alexe
- Department of Physical and Occupational Therapy, Faculty of Movement, Sports and Health, Sciences, "Vasile Alecsandri" University of Bacău, 600115 Bacău, Romania.
| | - Mariam Lahiani
- Research Laboratory Education, Motricité, Sport et Santé, LR19JS01, High Institute of Sport and Physical Education of Sfax, University of Sfax, Tunisia
| | - Rubén Sanchez-Gomez
- Nursing Department, Universidad Complutense de Madrid, Instituto de Investigacion Sanitaria, (IDISSC) Hospital Clinico San Carlos, 28040 Madrid, Spain
| | - Fatma Chaari
- Research Laboratory Education, Motricité, Sport et Santé, LR19JS01, High Institute of Sport and Physical Education of Sfax, University of Sfax, Tunisia
| | - Cristina Ioana Alexe
- Department of Physical Education and Sports Performance, Faculty of Movement, Sports and Health Sciences,"Vasile Alecsandri", University of Bacău, 600115 Bacău, Romania
| | - Dragos Ioan Tohanean
- Department of Motric Performance, "Transilvania" University of Brașov, 600115 Brașov, Romania
| | - Haithem Rebai
- Tunisian Research Laboratory 'Sports Performance Optimization', National Center of Medicine and Science in Sports (CNMSS), (CNMSS-LR09SEP01), Tunis, Tunisia
| | | | - Laurențiu Gabriel Talaghir
- Individual sports and physical therapy Department, "Dunarea de Jos" University of Galati str. Domnesca, nr, 47, Galati 800008, Romania
| | - Sonia Sahli
- Research Laboratory Education, Motricité, Sport et Santé, LR19JS01, High Institute of Sport and Physical Education of Sfax, University of Sfax, Tunisia
| |
Collapse
|
2
|
Dominguez I, Boni V, Garcia-Velloso MJ, Lopez-Vega JM, Martinez P, Plazaola A, Llombart A, Anton A, Galve E, Alvarez IM, Hernando B, Sanchez-Gomez R, Illarramendi JJ, Morales S, De JA, Richter JA, Lahuerta A, Garcia-Gonzalez M, Lao RJ, Puertolas T, Scherer S, Sabariz L, Garcia-Foncillas J. P2-09-02: Predicting Response to Bevacizumab in Primary Breast Cancer Using 18F-Fluorothymidina (FLT) and 18F-Misonidazole (MISO) Positron Emission/Computed Tomography (PET/CT) as Imaging Biomarkers. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-09-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: To investigate the hypothesis that early changes in tumor proliferation and hypoxic status induced by bevacizumab and assessed by imaging biomarkers might predict response to bevacizumab therapy.
Methods: 73 chemotherapy naïve, stage II-III breast cancer (BC) patients (pts) were enrolled in the training set of this phase II, single-arm, multicenter and prospective clinical trial from October 2009 until November 2010. Pts received single infusion of bevacizumab (15 mg/kg) (C1) 3 weeks prior to the beginning of neoadjuvant chemotherapy (NAC) consisting in 4 cycles of docetaxel (60 mg/mq), doxorubicin (50 mg/mq) and bevacizumab (15 mg/kg) every 21 days (C2-C5) following by surgery. Tumor proliferation and hypoxic status were evaluated using FLT and MISO PET/CT at baseline and 14–21 days after bevacizumab (C1). Standardized uptake values (SUV) for FLT and MISO and ratios to reference tissues, mediastinum (T/Me) or muscle (T/Mu), for MISO were calculated. Pathological response on surgical specimens was assessed according to Miller/Payne grading system. Pts with reduction in tumor cells >30% (G3-G4-G5) or <30% (G1-G2) were respectively considered as responders and no-responders. Association between pathological response, baseline and changes induced by bevacizumab (C1) in imaging biomarkers was analyzed using Mann-Whitney test. Receiver operating characteristic (ROC) curve was performed to test sensitivity and specificity of the biomarker found associated to response. Its value as independent predictor was tested in multivariate analysis using logistic regression. Results: Median baseline MISO and FLT SUV values in tumors were 1.2 (range 0.69−2.39) and 2.89 (range 0.97−7.18). Significant change after C1 was observed in FLT (2.7 vs 1.8, p<0.001) but no in MISO uptake. Fifty-two (74%) pts achieved response (G3-G4-G5) whether 18 (24%) were considered as no responder (G1-G2); for 3 (4%) patients Miller/Payne tumor evaluation was not available. Response showed a trend toward an association with negative estrogen receptors (ER) expression (p=0.08) and triple negative tumors (11/73) (p=0.05). FLT SUV baseline and changes after C1 in MISO SUV, T/Mu and T/Me were all significantly associated with pathological response (p=0.057, 0.03, 0.016, 0.010). ER expression and T/Mu change remained significantly associated with response in multivariate analysis (OR=24.8, IC95% 1.8-334, p=0.01 and OR=0.95, IC 95% 0.92−0.99, p value=0.02). Decrease in MISO T/Mu uptake >20% yielded a ROC curve area of 0.7 (95% CI: 0.56 - 0.85) with 94% sensitivity and 87% specificity. Conclusion: Bevacizumab determined a marked decrease in tumor proliferation. Interestingly, a decrease greater than 20% in tumor hypoxic status after C1 and assessed by MISO was found significantly associated with pathological response suggesting a potential value of early decrease in hypoxic tumor status as predictive biomarker of response. Bevacizumab, causing normalization of the tumor microvasculature, seems to potentiate the effect of cytotoxic agents on primary BC. A validation set is warranted to confirm these findings.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-09-02.
Collapse
Affiliation(s)
- I Dominguez
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - V Boni
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - MJ Garcia-Velloso
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - JM Lopez-Vega
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - P Martinez
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - A Plazaola
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - A Llombart
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - A Anton
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - E Galve
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - IM Alvarez
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - B Hernando
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - R Sanchez-Gomez
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - JJ Illarramendi
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - S Morales
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - Juan A De
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - JA Richter
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - A Lahuerta
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - M Garcia-Gonzalez
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - Romera J Lao
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - T Puertolas
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - S Scherer
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - Luis Sabariz
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| | - J Garcia-Foncillas
- 1Clinic University of Navarra; Hospital Marques de Valdecilla; Hospital de Basurto; Onkologikoa; Hospital Arnau de Villanova de Lleida; Hospital Miguel Servet; Hospital Civil de Basurto; Hospital Donostia; Hospital General Yagues de Burgos; Hospital de San Millan; Hospital de Navarra; Roche Basel; Roche Madrid
| |
Collapse
|